Structural Heart · Jun 9, 2026

Frailty and Clinical Outcomes After Isolated Tricuspid Valve Surgery: Implications for Future Transcatheter Tricuspid Intervention Trials

By von Stein J, Kundi H, Cohen DJ et al.

BACKGROUND: Frailty is recognized as a determinant of outcomes following valvular interventions; however, data on its prevalence and prognostic impact in patients undergoing isolated tricuspid valve (TV) surgery remain limited. We aimed to evaluate the prevalence of frailty and its association with outcomes in patients undergoing isolated TV surgery. METHODS: Among Medicare beneficiaries aged ≥65 years who underwent isolated TV surgery (2017-2023), frailty was assessed using the Hospital Frailty Risk Score and categorized as low (<5), intermediate (5-15), and high (>15). The primary outcome was all-cause mortality at 1 and 5 years. Secondary outcomes included in-hospital and 30-day mortality and prolonged hospitalization (≥10 days). Multivariable Cox models assessed associations between frailty and outcomes. RESULTS: Among 8179 patients (mean age 76 ± 7 years, 58% female), 58%, 33%, and 9% were classified as low, intermediate, and high frailty risk. Increasing frailty was associated with higher in-hospital mortality, 30-day mortality, and prolonged hospitalization (all p < 0.001). One-year mortality was 12.2% (95% CI: 11.3-13.2), 25.8% (95% CI: 24.1-27.6), and 35.8% (95% CI: 32.4-39.5) across frailty groups, with similar gradients observed at 5 years (all p < 0.001). Beyond 1 year, mortality increased more steeply in intermediate- and high-frailty patients. After adjustment, intermediate (hazard ratio: 1.18 [95% CI: 1.04-1.33]) and high frailty (hazard ratio: 1.32 [95% CI: 1.11-1.57]) remained independently associated with increased mortality. CONCLUSIONS: Among Medicare beneficiaries undergoing isolated TV surgery, frailty is common and independently associated with increased perioperative and long-term mortality. Routine frailty assessment may improve risk stratification and inform patient selection, with potential implications for clinical trial design.

doi.org/10.1016/j.shj.2026.101070Open accessPubMed 43054599Biomarkers

AgingResearch.News